What are the recommended pharmacologic treatments for ulcerative colitis in adults, including dosing regimens?

Drug Treatment of Ulcerative Colitis with Doses

For mild-to-moderate extensive or left-sided ulcerative colitis, start with mesalamine 2-4 g daily or balsalazide 6.75 g daily as first-line therapy; if inadequate response, escalate to prednisolone 40 mg daily tapered over 8 weeks, and for steroid-dependent disease, add azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day. 1

Treatment Algorithm by Disease Severity and Extent

Mild-to-Moderate Disease

First-Line: Aminosalicylates (5-ASA)

• Mesalamine: 2-4 g daily (standard to high dose)
  • High-dose (>3 g/day) more effective than standard dose (2-3 g/day) 2
  • Once-daily dosing comparable to divided doses for adherence 2
• Balsalazide: 6.75 g daily 1
• Olsalazine: 1.5-3 g daily (higher diarrhea incidence in pancolitis; best for left-sided disease) 1
• Sulfasalazine: 4 g daily (higher side effect profile; reserve for patients with reactive arthropathy) 1

Combined oral and rectal 5-ASA superior to oral alone for inducing remission 2

Second-Line: Corticosteroids (when 5-ASA fails or rapid response needed)

• Prednisolone: 40 mg daily orally
  • Taper gradually over 8 weeks (rapid reduction causes early relapse) 1
  • More effective than 20 mg/day; no benefit above 40-60 mg/day 3
• Beclomethasone dipropionate: 5 mg daily (prolonged-release tablet)
  • For patients wishing to avoid systemic corticosteroids 3
  • High first-pass metabolism, lower systemic effects

Steroid-Dependent Disease

Azathioprine: 1.5-2.5 mg/kg/day OR Mercaptopurine: 0.75-1.5 mg/kg/day 1

• Slow onset of action; requires induction with another agent
• Continue long-term to maintain remission 1

Important caveat: Thiopurine monotherapy NOT recommended for inducing remission in active disease 4

Moderate-to-Severe Disease (Advanced Therapies)

The 2024 AGA guideline provides the most current evidence for biologic and small molecule therapies 4:

Strong Recommendations (use over no treatment):

• Infliximab: 5 mg/kg IV (standard dosing)
  • Consider accelerated/intensified dosing for severe disease or hypoalbuminemia 5
• Golimumab
• Vedolizumab (subcutaneous formulation comparable to IV)
• Tofacitinib (JAK inhibitor)
• Upadacitinib (JAK inhibitor)
• Ustekinumab (biosimilars equivalent to originator)
• Ozanimod (S1P receptor modulator)
• Etrasimod (S1P receptor modulator)
• Risankizumab (anti-IL-23)
• Guselkumab (anti-IL-23)

Conditional Recommendations:

• Adalimumab (biosimilars available)
• Filgotinib (JAK inhibitor)
• Mirikizumab (anti-IL-23)

Critical FDA restriction: JAK inhibitors recommended only after TNF antagonist failure or intolerance in the United States 4. European Medicine Agency advises caution in patients ≥65 years, smokers, or those with cardiovascular disease history.

Network meta-analysis ranking (2026) for clinical remission 6:

1. JAK-STAT inhibitors (SUCRA 91.5% induction, 86.3% maintenance)
2. Anti-TL1A biologics (82.3% induction)
3. Anti-TNF-α biologics (70.1% induction)
4. S1P receptor modulators (80.5% maintenance)

Distal Colitis (Proctitis/Proctosigmoiditis)

Topical mesalamine: 1 g daily (suppositories for rectosigmoid; enemas for more proximal disease) 1

• Can add to oral therapy for troublesome rectal symptoms 1
• Topical steroids alternative if mesalamine not tolerated

Severe/Acute Severe UC (Hospitalized Patients)

First-Line:

Intravenous corticosteroids:

• Hydrocortisone: 400 mg/day IV OR
• Methylprednisolone: 60 mg/day IV 1

Salvage Therapy (steroid-refractory):

• Infliximab: 5 mg/kg IV (consider accelerated dosing) 5
• Cyclosporine: effective but requires specialist center 1
• Tofacitinib: as adjunct to IV corticosteroids improves short-term response 5
• Upadacitinib: promising when IV steroids and infliximab fail 5

Combination Therapy Considerations

TNF antagonists + immunomodulators: Suggested over monotherapy 4

• Particularly for infliximab therapy 3

Non-TNF biologics + immunomodulators: No clear recommendation (knowledge gap) 4

Maintenance Therapy

Lifelong maintenance recommended for all patients, especially left-sided/extensive disease 1

Options:

• Continue successful induction agent (except corticosteroids)
• Aminosalicylates for maintenance
• Azathioprine/mercaptopurine 1

De-escalation: In patients escalated to advanced therapies, SUGGEST stopping 5-ASA (low added benefit) 4

Do NOT withdraw TNF antagonists in patients achieving corticosteroid-free remission ≥6 months on combination therapy 4

Common Pitfalls to Avoid

1. Rapid steroid taper: Associated with early relapse; taper over 8 weeks minimum 1, 3
2. Long-term corticosteroid use: Undesirable; escalate to immunomodulators for steroid-dependent disease 1
3. Methotrexate monotherapy: NOT recommended for UC (unlike Crohn's disease) 4
4. Thiopurine monotherapy for active disease: Ineffective for induction due to slow onset 4
5. Ignoring JAK inhibitor restrictions: FDA mandates prior TNF failure in US 4
6. Premature discontinuation of maintenance therapy: Increases relapse risk, potentially increases colorectal cancer risk 1

Treatment Selection Hierarchy

The most recent evidence (2024-2026) demonstrates JAK inhibitors have optimal efficacy for both induction and maintenance 6, though regulatory restrictions apply. For treatment-naïve patients without contraindications, anti-TNF-α biologics remain first-line advanced therapy, with S1P receptor modulators and anti-IL-23 biologics as strong alternatives based on individual patient factors (cardiovascular risk, infection history, malignancy history, route preference).